Zydus Marks Strategic Entry into China with NMPA Approval for Venlafaxine ER Capsules

Zydus Lifesciences Limited has achieved a pivotal regulatory and commercial breakthrough by securing its first-ever approval from the National Medical Products Administration (NMPA) of China. This landmark approval is for Venlafaxine Extended-Release (ER) Capsules in the 75 mg and 150 mg strengths.

This milestone signifies Zydus’s successful navigation of China’s stringent regulatory processes and establishes a crucial foothold in one of the world’s fastest-growing pharmaceutical markets.

Critical Mental Health Therapy

Venlafaxine ER Capsules, an established medication globally, are indicated for treating several major psychiatric and anxiety disorders:

Major Depressive Disorder (MDD)
Generalised Anxiety Disorder (GAD)
Social Anxiety Disorder (SAD)
Panic Disorder (PD)

The medication functions as a Serotonin and Norepinephrine Reuptake Inhibitor (SNRI), working to restore the balance of these key neurotransmitters in the brain to effectively improve mood and alleviate anxiety symptoms.

Manufacturing and Market Strategy

The Venlafaxine ER Capsules destined for the Chinese market will be produced at Zydus’s state-of-the-art manufacturing facility located in Moraiya, Ahmedabad, India.

This initial NMPA approval is a strategic precursor for Zydus’s broader expansion plans in China, indicating the company’s commitment to bringing its portfolio of quality, affordable medicines to the vast Chinese patient population suffering from mental health conditions.